AKBA

Companies
NASDAQ
Akebia Therapeutics Inc.
Health Care
Price Chart
Overview

About AKBA

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.

Market Cap
$222.2M
Volume
16.1M
Avg. Volume
18.5M
P/E Ratio
-6.923077
Dividend Yield
0.00%
Employees
260.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.49
High Correlation
Volatility
High (0.67)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for AKBA.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, AKBA shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$222.2M
Volume16.1M
P/E Ratio-6.92
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 13, 2025

PortfolioPilot Analysis

Get AI-powered insights on how AKBA fits into your investment strategy and portfolio diversification.

Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025